30
Oversold
Moving averages
SMA 200$2.70-39.26%
Company profile
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
SectorHealthcare
IndustryBiotechnology
Market cap$367.33M
P/E ratioNone
EPS$-0.54
Beta2.077
Dividend yield0.00%
52-week high$3.94
52-week low$1.66
Similar stocks in Biotechnology
BNTX
BioNTech SE
RSI 32
VRTX
Vertex Pharmaceuticals Inc
RSI 43
CRSP
CRISPR Therapeutics AG
RSI 27
IOVA
Iovance Biotherapeutics Inc
RSI 31
ALT
Altimmune Inc
RSI 23
AGEN
Agenus Inc
RSI 44
OCGN
Ocugen Inc
RSI 39
DTIL
Precision Biosciences Inc
RSI 45
ALLO
Allogene Therapeutics Inc
RSI 19
ARCT
Arcturus Therapeutics Holdings Inc
RSI 36
RSI alerts for EDIT
An email when EDIT closes below RSI 30 or above 70. Nothing else.
Data last updated 13 November 2026 at 1:32 AM EST